Work

Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2584

Authors: Apostolia Maria Tsimberidou, Claire F. Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John J. Nemunaitis, Christine Hicking, Jamie Shaw, Remigiusz Kaleta, Razelle Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, The Barbara Ann Karmanos Cancer Institute, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, University of Miami Health System, Sylvester Comprehensive Cancer Center, University of Toledo, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Moores Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891879746

Cites:

Cited by: 2

Related to: 10